Pidnarulex (CX-5461) + Cemiplimab (Libtayo®) combo to be tested in Ph 1/2 clinical trial for MSS CRC patients September 23, 2025
Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked ADC September 23, 2025
Bayer and Kumquat Biosciences enter global exclusive license and collaboration in precision oncology September 16, 2025
TREOS Bio, Charité Berlin, and Junshi Biosciences to Launch Pivotal Ph 2 Trial of PolyPEPI1018, toripalimab, and SoC combo in Refractory MSS CRC September 3, 2025
FDA granted Breakthrough Therapy Designation and Orphan Drug Designation for D3S-001 for Patients with KRAS G12C-Mutated Cancers September 3, 2025
FDA clears IND application of 7MW4911 to initiate Ph 1/2 trial in patients with advanced CRC and other advanced gastrointestinal tumors August 26, 2025
CTMX-2051-101 study remains active and patients continue to be dosed with CX-2051 across all expansion doses August 19, 2025
ELI-002 Updated AMPLIFY-201 Ph 1 Follow-up Data published in Nature Medicine for MRD Positive, Adjuvant-Stage Patients August 19, 2025
German federal authority approves CTA to initiate Ph 1/2a trial of CC-38 in patients with metastatic CRC and metastatic prostate cancer August 19, 2025
Positive Data Announced from Ph 2 CRDF-004 trial of onvansertib in 1L RAS-mutated mCRC August 5, 2025
FDA Clears IND application for Ph 1/2 Trial of ABT-301 Triplet Therapy for Advanced CRC August 5, 2025
Regulatory Update on Clinical Development Plan for Muzastotug in MSS-CRC Announced Following Productive Type B (End of Ph 1) Meeting with FDA July 23, 2025
First Patient Enrolled in Ph 3 AK112-312/HARMONi-GI6 Trial of Ivonescimab for 1L Metastatic CRC July 23, 2025
CRC Cohort of Ph 2 Trial of PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results July 15, 2025
SIR-Spheres® Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable HCC July 15, 2025
BRAFTOVI® (encorafenib) combo approved in China for treating previously-treated BRAFV600E-mutant metastatic CRC July 15, 2025
Encouraging Survival Data in Patients with Metastatic CRC Previously Treated with Leronlimab Announced July 8, 2025
Data from Ongoing Dose Escalation of BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma presented July 8, 2025
BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Ph 3 July 8, 2025
